Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CHEK2 |
Variant | I221M |
Impact List | missense |
Protein Effect | no effect - predicted |
Gene Variant Descriptions | CHEK2 I221M lies within the protein kinase domain of the Chek2 protein (UniProt.org). I221M results in cell proliferation similar to wild-type Chek2 in a yeast assay (PMID: 30851065), and therefore, is predicted to have no effect on Chek2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
CHEK2 mutant CHEK2 I221M |
Transcript | NM_007194.4 |
gDNA | chr22:g.28719415G>C |
cDNA | c.663C>G |
Protein | p.I221M |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_145862 | chr22:g.28719415G>C | c.663C>G | p.I221M | RefSeq | GRCh38/hg38 |
NM_007194.3 | chr22:g.28719415G>C | c.663C>G | p.I221M | RefSeq | GRCh38/hg38 |
NM_145862.2 | chr22:g.28719415G>C | c.663C>G | p.I221M | RefSeq | GRCh38/hg38 |
NM_001349956.2 | chr22:g.28703549A>C | c.663T>G | p.I221M | RefSeq | GRCh38/hg38 |
NM_007194 | chr22:g.28719415G>C | c.663C>G | p.I221M | RefSeq | GRCh38/hg38 |
NM_007194.4 | chr22:g.28719415G>C | c.663C>G | p.I221M | RefSeq | GRCh38/hg38 |
NM_001349956.1 | chr22:g.28703549A>C | c.663T>G | p.I221M | RefSeq | GRCh38/hg38 |
NM_145862.2 | chr22:g.28719415G>C | c.663C>G | p.I221M | RefSeq | GRCh38/hg38 |
XM_011529843 | chr22:g.28703549A>C | c.663T>G | p.I221M | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CHEK2 mutant | prostate cancer | not applicable | N/A | Guideline | Risk Factor | Germline CHEK2 mutations are associated with increased risk of developing prostate cancer (NCCN.org). | detail... |
CHEK2 mutant | Advanced Solid Tumor | no benefit | Olaparib | Phase II | Actionable | In a Phase II trial, Lynparza (olaparib) treatment did not demonstrate clinical activity in patients with advanced solid tumors harboring ATM (n=13) or CHEK2 (n=14) mutations (Ann Oncol (2023) 34 (suppl_2): S242; NCT03967938). | detail... |
CHEK2 mutant | breast cancer | no benefit | Olaparib | Case Reports/Case Series | Actionable | In a Phase II trial (TBCRC 048), Lynparza (olaparib) treatment did not result in an objective response in 7 patients with metastatic breast cancer harboring only germline mutations in CHEK2 (PMID: 33119476; NCT03344965). | 33119476 |
CHEK2 mutant | breast cancer | not applicable | N/A | Guideline | Risk Factor | Germline CHEK2 mutations are associated with increased risk of developing breast cancer (NCCN.org). | detail... |